STAT3 and prostate carcinoma: In a mouse model of conditional Pten-null prostate cancer, Toso and colleagues discovered that STAT3 inactivation, either by genetic knockout or pharmacological JAK2 (an upstream activator of STAT3) inhibition, modifies SASP composition without affecting the establishment of senescence and the subsequent cell growth arrest [7].